Compare TG Therapeutics Inc (TGTX) vs Wolfspeed Inc (WOLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
TG Therapeutics Inc vs Wolfspeed Inc — how do they compare? TG Therapeutics Inc trades at $49.69 (market cap $7.64B), while Wolfspeed Inc trades at $32.05 (market cap $1.57B). The key difference: TG Therapeutics Inc is far larger — about 4.9× Wolfspeed Inc's market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Wolfspeed Inc nearer its low. Which is the better fit depends on your goals.
| TGTX | WOLF | |
|---|---|---|
Market Cap | $7.64B | $1.57B |
Sector | Health | Technology |
52-Week High | $59.06 | $73.68 |
52-Week Low | $26.94 | $1.19 |
Enterprise Value | $7.84B | $2.22B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TGTX trades at $50.26, up 2.24% in the last session, with a bearish technical signal from moving averages despite neutral oscillators. Recent Q2 2026 earnings missed estimates at $0.05 per share versus $0.3057 expected, though revenue surged to $240 million, driven by strong BRIUMVI sales growth of 64% year-over-year. The company raised 2026 revenue guidance to $950 million, reflecting robust demand for its multiple sclerosis treatment.
The outlook is mixed: strong revenue growth and a high analyst buy consensus (84.62%) support upside to the $63.75 price target, but earnings misses, a high EV/EBITDA of 56.26, and a shareholder investigation into fiduciary breaches pose risks. Investors should weigh the growth potential against execution and regulatory uncertainties.
WOLF trades at $31.53, up 7.61% today, with bullish technical indicators showing strong momentum above key support levels. The company shows negative profitability metrics but has beaten earnings estimates in two of the last three quarters. Recent strategic partnerships with LITEON and GE Aerospace position WOLF for growth in AI data center and aerospace markets.
While technical momentum is positive, fundamental challenges persist with negative margins and ROE. Analyst sentiment is mixed with 32% buy ratings. The stock offers growth potential in silicon carbide technology markets but carries significant execution and profitability risks that require careful monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →About Wolfspeed Inc
Wolfspeed is the global leader in wide bandgap semiconductors, specializing in silicon carbide (SiC) and gallium nitride (GaN) materials and devices. It operates a vertically integrated model, controlling the entire process from raw material substrate production to advanced power modules, serving as a critical infrastructure provider for electric vehicles (EVs), renewable energy, and AI data centers.
Read more on WOLF →
